Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman joined Steve Darling from Proactive to share important news about the company's drug development priorities. Tonix Pharmaceuticals has announced that it will prioritize the development of TNX-4300, which is the single-isomer of tianeptine, over TNX-601 ER*. TNX-4300 is currently in preclinical development for mood disorders, Alzheimer's disease, and Parkinson's disease. Recent findings have shown that estianeptine, the active component of TNX-4300, has the potential to improve memory and cognition in vivo, as measured in the rat Novel Object Recognition test. Additionally, estianeptine has demonstrated the ability to restore neuroplasticity to neurons in cell culture.
These findings suggest that the activation of the peroxisome proliferator-activated receptor PPAR-β/δ might play a role in memory improvement. In light of these promising results, Tonix Pharmaceuticals has decided to accelerate the completion of enrollment for the Phase 2 UPLIFT1 trial, which is studying TNX-601 ER for the treatment of major depressive disorder. The resources will be reallocated to expedite the preclinical development of TNX-4300. The company now expects to report topline data from the UPLIFT1 trial in the fourth quarter of 2023. Furthermore, Tonix is also fast-tracking the enrollment for the RESILIENT study of TNX-102 SL for the management of fibromyalgia. Approximately 450 patients will be enrolled in this study, and topline results are anticipated to be available in the fourth quarter of 2023. The decision to prioritize TNX-4300 over TNX-601 ER* is based on the encouraging preclinical data and the potential for TNX-4300 to address multiple therapeutic areas effectively. The accelerated timelines for the clinical trials are expected to advance the development of these potential treatments, which could have significant implications for patients suffering from mood disorders, memory-related issues, and fibromyalgia.